secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0000950170-23-034560
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa appoints former Momenta CSO Anthony Manning to Board
---------------------------------------------------------------

- Board expanded from 8 to 9 directors; Dr. Manning fills newly created vacancy, effective July 25, 2023.
- He will serve as a Class II director until the 2026 annual meeting of stockholders.
- Board determined Manning is independent under Nasdaq listing standards.
- Manning was CSO at Momenta Pharma, which was acquired by J&J for $6.5B in 2020; expertise in autoimmune disease and drug discovery.
- He will receive cash and equity compensation per the company's non-employee director policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/0000950170-23-034560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/glue-20230726.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-034560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer